Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy

Helmers, Sandra L.; Duh, Mei Sheng; Guérin, Annie; Sarda, Sujata P.; Samuelson, Thomas M.; Bunker, Mark; Olin, Bryan; Jackson, Stanley D.; Faught, Edward

doi:10.1016/j.yebeh.2011.07.020

Cited by 62 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the average time spent on epilepsy-related tasks for these patients is significantly reduced (p < 0.001). In their series of more than 1600 patients about the long-term impact of VNS therapy on resource utilization, Helmers et al [49] reported a significant reduction in both epilepsy-related and overall health care costs of these patients, resulting in net cost savings after about 1.5 years from implantation. Related to pediatric patients, hospital admissions and emergency room visits are decreased after VNS therapy [50,51] and given the long life expectancy in those patients, these results may translate into a significant cost savings over time.…”

Section: Discussionmentioning

confidence: 99%

Vagus nerve stimulation therapy for treatment-resistant epilepsy: A 15-year experience at a single institution

Galbarriatu

Pomposo

Aurrecoechea

et al. 2015

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Vagus nerve stimulation therapy for treatment-resistant epilepsy: A 15-year experience at a single institution

Galbarriatu

Pomposo

Aurrecoechea

et al. 2015

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

“…VNS cost analyses have shown similar or greater long-term cost-effectiveness compared to care as usual [15-17]. Helmers et al [17] showed that patients with drug-resistant epilepsy who underwent VNS typically experienced a net cost savings after 1.5 years.…”

Section: Discussionmentioning

confidence: 99%

“…Helmers et al [17] showed that patients with drug-resistant epilepsy who underwent VNS typically experienced a net cost savings after 1.5 years. At this point the average postoperative cost savings outweighed the initial preprocedure costs, including expenses related to the device and operation.…”

Section: Discussionmentioning

confidence: 99%

A Comparison of Vagal Nerve Stimulation and Responsive Neurostimulation for the Treatment of Medically Refractory Complex Partial Epilepsy

Ellens

Elisevich²,

Burdette³

et al. 2018

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Background: Neuromodulatory applications such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are safe and effective strategies for medically intractable epilepsy secondary to complex partial seizures, but researchers have yet to compare their efficacies. Objective: The goal of this study is to compare VNS and RNS efficacy at reducing seizure frequency and complication rates in subjects with medically intractable epilepsy secondary to complex partial seizures. Methods: This is a retrospective chart review of 30 patients with medically intractable complex partial epilepsy, who underwent either VNS or RNS placement at a single institution between June 2012 and January 2016. There was a mean follow-up of 19 months. Seizure frequency reduction and complications were identified. Results: The median seizure frequency reduction was similar for VNS (66%) and RNS (58%). There was no major morbidity or mortality, and the frequency of minor complications was similar between VNS (15%) and RNS (18%). Conclusion: We found that VNS and RNS reduced the median seizure frequency similarly with no difference in morbidity or mortality. Further prospective studies are warranted as VNS and RNS therapy improves over time.

show abstract

“…Based on clinical observations, effects of treatment varies and VNS decreases the frequency and severity of seizure. [7,8] Here, in this study we investigated the effects of VNS treatment in patients with phamacoresistant epilepsy.…”

Section: Discussionmentioning

confidence: 99%

“…VNS therapy was approved in Europe in 1994 and by the US Food and Drug Administration in 1997 (data on file, Cyberonics, Inc., Houston , TX). [7,8] First VNS implantation was applied in 1998 in Turkey. [9] Currently used implantation conditions were determined by Social Insurance Institution in 2009.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Vagus Nerve Stimulation in Patients with Drug Resistant Epilepsy

Nalbantoğlu¹,

Özkara²,

Yeni³

et al. 2014

Epilepsi

View full text Add to dashboard Cite

SummaryObjectives: Vagal nerve stimulation (VNS), is an adjunctive therapy approved for use in patients with refractory epilepsy, based on stimulation of the exctracranial part of the vagus nerve. In this study, we provide an analysis of seizure outcomes after VNS implantation for pharmacologically resistant epilepsy patients. Methods:We reviewed all patients who had VNS implantation in our center from 2005 to June 2013. Patient outcomes were evaluated using the VNS-specific outcome scale.Results: This study consisted of 35 patients (24 males, 11 females; mean age 13.7±8.2 years, range 7 to 40 years). The mean age at VNS implantation was 17.17±8.4 years (range 4 to 35 years). The mean duration of VNS therapy was 26±19.2 months (range 3 to 84 months). The 80% of our patients were in the responders, 20% of them were in the nonresponders group. Conclusion: Vagal nerve stimulation, is an alternative treatment approach. Given the potential for cognitive, behavioural improvement with or without improved seizure control, VNS may be considered in the course of treatment of refractory epilepsy.Key words: Refractory epilepsy; vagal nerve stimulation; VNS. ÖzetAmaç: Vagal sinir stimülasyonu (VNS), tedaviye dirençli epilepsi hastalarında uygulanan, vagal sinirin ekstrakraniyal bölümünün uyarımına dayanan, alternatif bir tedavi yöntemidir. Bu çalışmada, ilaç tedavisine dirençli olup VNS uygulanan hastalar gözden geçirilerek sonuçlar değerlendirildi. Gereç ve

show abstract

Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy

Cited by 62 publications

References 28 publications

Vagus nerve stimulation therapy for treatment-resistant epilepsy: A 15-year experience at a single institution

Vagus nerve stimulation therapy for treatment-resistant epilepsy: A 15-year experience at a single institution

A Comparison of Vagal Nerve Stimulation and Responsive Neurostimulation for the Treatment of Medically Refractory Complex Partial Epilepsy

Efficacy of Vagus Nerve Stimulation in Patients with Drug Resistant Epilepsy

Contact Info

Product

Resources

About